Burgess Hill & Villages PCN

With 21.4% aged 65+, older patients and 17 care homes shape network demand

Burgess Hill & Villages PCN has 55,141 registered patients. Patients aged 65+ represent 21.4% (11,825), above Mid Sussex (19.9%), in line with NHS Sussex ICB (21.5%), and above England (17.6%). Those aged 0–17 comprise 20.1% (11,110 patients), compared to Mid Sussex (20.8%), NHS Sussex ICB (17.7%), and England (19.4%). Census usual-resident estimates—not registered patients—show 93.0% White ethnicity (Mid Sussex 92.3%, NHS Sussex ICB 91.0%, England 81.1%) and a 7.0% non-White share. Projected list growth to 2030 is 3.7% (Mid Sussex 2.4%, NHS Sussex ICB 2.1%, England 2.3%), though projection methods are unverified.

Zero Core20 patients across all practices shifts inequality priorities to clinical inclusion cohorts

Burgess Hill & Villages PCN has an average IMD decile of 8.3, matching Mid Sussex (8.3 decile) and above NHS Sussex ICB (6.1 decile) and England (5.5 decile). Across all 4 practices and 55,141 registered patients, 0.0% live in Core20 areas, against 0.0% in Mid Sussex, 9.2% in NHS Sussex ICB and 21.0% in England. With national area indices capturing zero local patients, health inequality work could focus on practice clinical registers, including 414 patients with severe mental illness and 234 with learning disabilities.

PLUS groups and inclusion health

The PCN records 414 severe mental illness patients (0.8%) and 234 with learning disabilities (0.4%), holding 29.9% and 32.2% of borough registers respectively, alongside 17 catchment care homes (587 beds). Recorded prevalence trails England for severe mental illness (0.8% vs 1.0%) and learning disability (0.4% vs 0.6%), though crude register differences do not establish under-detection or coding variations.

Severe mental illness: physical health checks

SMI blood pressure checks reached 87.4% and BMI recording 85.8%, exceeding England (83.4% and 82.1%). Smoking cessation offers for condition registers fell 5.2 pp over 2023 to 2025 to 91.6% (England 94.2%), with Mid Sussex Health Care at 81.3%.

Clinical focus: hypertension and lipids

Hypertension case-finding and control

The hypertension register grew +6.3% over 2023 to 2025 to 8,464 patients (15.8% prevalence, England 15.2%, Mid Sussex 16.1%, NHS Sussex Integrated Care Board 16.3%). Blood pressure control under age 80 fell 7.2% over 2023 to 2025 to 67.2% (England +3.2%, Mid Sussex -1.8%, NHS Sussex Integrated Care Board +4.5%), while treatment to threshold fell 5.3% to 70.2% (England +3.7%, Mid Sussex -0.7%, NHS Sussex Integrated Care Board +3.8%). Slipping control rates could reflect recall capacity or coding differences to verify locally, leaving patients at risk of unmanaged hypertension.

Lipids and statins

For patients with QRISK ≥ 20%, lipid-lowering therapy reached 60.8% (England 63.6%), despite +9.0% growth over 2023 to 2025 (England +6.2%). CKD statin coverage was 68.2%, trailing England (70.3%) but above Mid Sussex (66.2%). Lower statin initiation relative to England may indicate gaps in primary prevention recall.

In 2025, cardiovascular system drugs cost £4.65 per item (England £3.33; £115,883 more than at England's unit cost, across 87,790 items). Cholesterol and hyperlipidemia items cost £2.46 (England £1.82; £33,787 more than at England's unit cost, across 52,792 items). These unit-cost indicators reflect formulary or mix differences rather than established inefficiency or savings targets.

Clinical focus: respiratory, cancer register and children

Respiratory

Asthma prevalence is 7.5% across 3,763 patients (England 6.6%), with annual reviews rising +10.9% over 2023 to 2025 to 64.6% (England 65.7%, Mid Sussex 66.3%), leaving a scale indicator of about 1,300 unreviewed patients. COPD prevalence is 1.4% across 779 patients (England 1.9%), with reviews at 75.2% (England 76.4%, Mid Sussex 78.4%) and three-year growth at +0.4% (England +2.7%, Mid Sussex +8.8%). Unreviewed respiratory patients could face risks of unmanaged exacerbations.

Cancer register and children's immunisation

Cancer register prevalence is 4.8% (2,554 patients; England 3.8%). In Q1 2025/26, age-5 MMR dose 1 coverage reached 95.4% (England 91.7%), while dose 2 reached 90.7% (England 82.8%), showing a 4.7 pp drop between doses and sitting 4.3 pp below the 95.0% target.

Early cancer diagnosis

In 2022, 58.5% of staged cancers (4,799 of 8,209) across NHS Sussex ICB were diagnosed at stage 1 or 2, exceeding England (55.3%) but sitting 16.5 pp below the 75.0% national ambition by 2028. Staging was recorded for 64.3% of all registered cancers (8,209 of 12,766; England 67.0%). Closing this gap across the ICB would require about 1,360 extra early-stage diagnoses annually. PCN cervical screening coverage is 74.2% (England 66.8%), but fell 1.9% over 2023 to 2025 (England -1.0%), with Brow Medical Centre trailing at 64.4%. System stage data reflects ICB recording rather than PCN performance, but primary care screening uptake remains critical.

Cancer waits, diagnostics and community services

Cancer waits and diagnostics, Jul 2026 (provisional)

In July 2026, University Hospitals Sussex NHS Foundation Trust achieved 65.2% on the cancer 62-day referral to treatment standard, below the 85.0% standard by 19.8 pp and trailing NHS Surrey and Sussex Integrated Care Board (71.5%) and England (71.2%). The trust met 74.0% for the 28-day faster diagnosis standard (standard 75.0%, England 79.3%) and 76.8% for 31-day combined treatment (standard 96.0%, England 92.5%). Diagnostic 6-week waits averaged 12.9% overall (England 23.1%), but reached 39.3% for colonoscopy and 45.4% for flexi sigmoidoscopy. These provider waiting times reflect acute trust activity rather than PCN delivery.

Practice phone access and vaccination achievement vary sharply despite high clinical QOF scores

In 2025/26, clinical QOF achievement reached 100.0% at three practices and 96.3% at Mid Sussex Health Care against England's 97.1%. However, vaccination and immunisation achievement spanned 51.3 pp, from 41.8% at Mid Sussex Health Care (England 55.2%) to 93.0% at Silverdale Practice, showing uneven delivery behind high overall scores.

17 of 25 tracked measures trail England's change, led by heart failure reviews

Across 25 tracked indicators, 17 trail England's three-year change over 2023 to 2025. The widest lag is in annual heart failure functional reviews, which fell 11.8% to 73.4% (England +8.7%, 78.5%; Mid Sussex +4.1%). Dementia recorded prevalence also contracted 2.4% to 0.9% (England +6.0%, Mid Sussex +2.3%). Conversely, strengths include asthma reviews, which rose +10.9% (England +4.4%), and alcohol recording for psychosis, up +10.6 pp (England +5.3 pp). Slipping chronic disease reviews could reflect recall capacity constraints to verify locally through clinical audit.

What the data can't tell us: gaps and local assets

Options for the PCN

Each option in full

Provenance and audit trail

Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.

Data sources

Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.

Methods, data-quality notes and limitations